The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Open accessPublished version of a preprint
Abstract
Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations. The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients. Experimental Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and negative cases were then assessed for HER2 mutations (exons 19–20) using a sizing assay and mass spectrometry. Testing for additional recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry. ALK rearrangements and HER2 amplification were assessed by FISH. Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-negative specimens. Small insertions in exon 20 accounted for 96% (24/25) of the cases. Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775. Morphologically, 92% (23/25) were moderately or poorly differentiated ADC. HER2 mutation was not associated with concurrent HER2 amplification in 11 cases tested for both. HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no associations with sex, race, or stage. Conclusions: HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2. Clin Cancer Res; 18(18); 4910–8. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Exon 20 of EGFR and HER2 contains two major regions, the α-C helix (residues 762–766 in EGFR and 770–774 in HER2) and the loop following the α-C helix (residues 767–774 in EGFR and 775–783 in HER2)16,19,20,27.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“Together, EGFR and HER2 exon 20 mutations are found in approximately 4% of all patients with NSCLC19.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [19]
In the citing paper
“with the A775_G776insYVMA mutation accounting for most of the mutations seen in NSCLC (17–21).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Cited by
Sorted by citations
Items 201–300 of 506
Lee, K.-K., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.186 · Cited by 24
Emerging Targets in Advanced Non-Small-Cell Lung Cancer
Valentino, F., Borra, G., Allione, P., & Rossi, L. (2018) · Future Oncology · doi:10.2217/fon-2018-0099 · Cited by 23
Liu, Z., Zhang, H., Sun, J., Zheng, M., Cui, L., Zhang, Y., Cheng, J., Tang, Z., & Chen, X. (2023) · Advanced Materials · doi:10.1002/adma.202300377 · Cited by 23
Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Giustini, N., Jeong, A., Buturla, J. A., & Bazhenova, L. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.003 · Cited by 23
Aliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 22
MET: A New Promising Biomarker in Non-Small-Cell Lung Carcinoma
Pérez-Ramírez, C., Cañadas‐Garre, M., Jiménez‐Varo, E., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.11 · Cited by 23
Shan, L., Qiu, T., Ling, Y., Guo, L., Zheng, B. J., Wang, B., Li, W., Li, L., & Ying, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130447 · Cited by 22
Lategahn, J., Hardick, J., Grabe, T., Niggenaber, J., Jeyakumar, K., Keul, M., Tumbrink, H. L., Becker, C., Hodson, L. E., Kirschner, T., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00870 · Cited by 22
Shao, J., Yin, J. C., Bao, H., Zhao, R., Han, Y., Zhu, L., Wu, X., Shao, Y. W., & Zhang, J. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.197 · Cited by 22
Felip, E., Concha, Á., de Castro, J., Gómez‐Román, J., Garrido, P., Ramírez, J., Isla, D., Sanz, J., Paz-Ares, L. G., & López‐Ríos, F. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1248-9 · Cited by 21
Updates in the molecular pathology of non-small cell lung cancer
Paver, E. C., O'Toole, S. A., Cheng, X. M., Mahar, A. M., & Cooper, W. A. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.04.001 · Cited by 21
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Kaur, M., & Singh, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.021 · Cited by 21
Malapelle, U., Muscarella, L. A., Pisapia, P., & Rossi, A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1732922 · Cited by 23
Somaiah, N., Fidler, M. J., Garrett-Mayer, E. S., Wahlquist, A. H., Shirai, K., Buckingham, L. E., Hensing, T. A., Bonomi, P., & Simon, G. R. (2014) · Oncoscience · doi:10.18632/oncoscience.72 · Cited by 21
written on behalf of the AME Lung Cancer Collaborative Group, Feng, Y., Feng, G., Lu, X., Qian, W., Ye, J., Manrique, C. A., Ma, C., & Lu, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.108 · Cited by 20
Acquired Resistance in Lung Cancer
Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21
Zhao, F., Ge, F., Xie, M., Li, Z., Zang, C., Kong, L., Pu, Y., Zheng, X., & Tan, Y. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10169-4 · Cited by 20
Kato, Y., Udagawa, H., Matsumoto, S., Izumi, H., Ohe, Y., Kato, T., Nishino, K., Miyamoto, S., Kawana, S., Chikamori, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107992 · Cited by 19
Comparable clinical outcomes in patients with HER2‐mutant and EGFR‐mutant lung adenocarcinomas
Gow, C., Chang, H., Lim, C., Liu, C., Chen, J., & Shih, J. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22442 · Cited by 19
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Vathiotis, I. A., Charpidou, A. G., Gavrielatou, N., & Syrigos, K. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121300 · Cited by 20
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 22
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
Xie, H., & Adjei, A. A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.034 · Cited by 19
Auliac, J. B., Dô, P., Bayle, S., Doubre, H., Vinas, F., Letreut, J., Falchero, L., Hauss, P. A., Thomas, P. A., & CHOUAID, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01001-9 · Cited by 19
Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19
Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy
Villalobo, A., García‐Palmero, I., Stateva, S. R., & Jellali, K. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3v59v · Cited by 19
Yuan, B., Zhao, J., Zhou, C., Wang, X., Zhu, B., Zhuo, M., Dong, X.-L., Feng, J., Yi, C., Yang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00729 · Cited by 17
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
Volckmar, A., Christopoulos, P., Kirchner, M., Allgäuer, M., Neumann, O., Budczies, J., Rempel, E., Horak, P., Glade, J., Goldschmid, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.022 · Cited by 18
Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer
Zhang, S., Wang, W., Xu, C., Zhang, Y., Cai, X., Wang, Q., Song, Z., Li, Z., Yu, J., Zhong, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14743 · Cited by 17
Simarro, J., Pérez-Simó, G., Mancheño, N., Ansótegui, E., Muñoz-Núñez, C. F., Gómez‐Codina, J., Juan, Ó., & Palanca, S. (2023) · Cancers · doi:10.3390/cancers15061705 · Cited by 18
Re, M. D., Vasile, E., Falcone, A., Danesi, R., & Petrini, I. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.908120 · Cited by 18
Bhaumik, S., Ahmad, F., & Das, B. R. (2016) · Medical Oncology · doi:10.1007/s12032-016-0828-7 · Cited by 18
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
Liao, B.-C., Lin, C., & Yang, J. C. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0560-2 · Cited by 18
Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis
Layfield, L. J., Hammer, R., White, S., Furtado, L. V., & Schmidt, R. L. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0218-oa · Cited by 19
Dacomitinib in Non-Small-Cell Lung Cancer: A Comprehensive Review for Clinical Application
Sun, H., & Wu, Y.-L. L. C. (2019) · Future Oncology · doi:10.2217/fon-2018-0535 · Cited by 19
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Nokin, M., Ambrogio, C., Nadal, E., & Santamaría, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 21
Zhang, S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R. L., Venkatakrishnan, K., & Gupta, N. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.951 · Cited by 18
Gao, X., Yu, G. Y., Hong, Y. G., Lian, W., Chouhan, H. S., Xu, Y., Liu, L., Bai, C. G., & Zhang, W. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1377-1 · Cited by 18
Emerging Biomarkers in Personalized Therapy of Lung Cancer
Cagle, P. T., Raparia, K., & Portier, B. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_2 · Cited by 16
Lee, Y., Lee, B., Choi, Y., Kang, D., & Han, J. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100490 · Cited by 19
Zhao, J., Chen, X., Zheng, J., Kong, M., Wang, B., & Ding, W. (2018) · Histopathology · doi:10.1111/his.13492 · Cited by 17
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Liu, Y., Yu, C., Yang, J. C., & Shih, J. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22647 · Cited by 18
Lung cancer incidence in never smokers: Genetic and gender basis
Peddireddy, V. (2016) · Gene Reports · doi:10.1016/j.genrep.2016.06.003 · Cited by 17
Tan, A. C., Saw, S. P. L., Chen, J., Lai, G. G. Y., Hlaing, N. O., Takano, A. M., Lau, D. P., Yeong, J. P.-S., Tan, G. S., Lim, K. H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00278 · Cited by 18
Reis, H., Herold, T., Ting, S. C., Worm, K., Huber, U., Christoph, D. C., Eberhardt, W., Kostbade, K., Kasper, S., Stamatis, G., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.002 · Cited by 16
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors
Kanthala, S., Pallerla, S., & Jois, S. D. S. (2015) · Future Oncology · doi:10.2217/fon.14.312 · Cited by 16
Liu, Y., Teng, F., Zheng, X., Brown, M. A., Zhang, P., Liu, X. S., & Wang, H. (2016) · Scientific Reports · doi:10.1038/srep22120 · Cited by 16
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Quintanal-Villalonga, À., Paz-Ares, L. G., Ferrer, I., & Molina‐Pinelo, S. (2016) · Disease Markers · doi:10.1155/2016/9214056 · Cited by 16
Yang, G., Hao, X., Hu, J., Dong, K., Xu, H., Yang, L., Zhang, S., Yang, Y., Xu, F., Li, J., et al. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.08.001 · Cited by 15
Topalan, E., Büyükgüngör, A., Çiğdem, M., Gura, S. F., Sever, B., Otsuka, M., Fujita, M., DeMirci, H., & Ciftci, H. I. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400992 · Cited by 18
Steroidal saponins: Natural compounds with the potential to reverse tumor drug resistance (Review)
Cui, A., Liu, H., Liu, X., Zhang, M., Xiao, B., Wang, B., & Yang, J. (2024) · Oncology Letters · doi:10.3892/ol.2024.14719 · Cited by 18
Biomarker testing in lung cancer: from bench to bedside
Batra, U., & Nathany, S. (2025) · Oncology Reviews · doi:10.3389/or.2024.1445826 · Cited by 17
Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates
Kamata, T., Yoshida, A., Shiraishi, K., Furuta, K., Kosuge, T., WATANABE, S.-I. I., Asamura, H., & Tsuta, K. (2015) · Histopathology · doi:10.1111/his.12763 · Cited by 15
Shi, Y., & Wang, M. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12906 · Cited by 15
Zhao, S., Xian, X., Tian, P., Li, W., Wang, K., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633522 · Cited by 15
Sun, S., Du, W., Sun, Q., Zhao, X. Q., Qin, B., Shi, D., Wan, C., & Wu, Z. (2021) · Cancer Medicine · doi:10.1002/cam4.4178 · Cited by 13
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
Tawfiq, R. K., Correia, G. S. D. C., Li, S., Zhao, Y., Lou, Y., & Manochakian, R. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01655-5 · Cited by 14
Organoids in Lung Cancer Management
Li, Y., Chan, J. W. Y., Lau, R. W. H., Cheung, W. W. Y., Wong, A. M., Wong, A. M., Wong, N., & Ng, C. S. H. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.753801 · Cited by 14
Bontoux, C., Benzaquen, J., Hofman, V., Heeke, S., Hannetel, P., Capela-Brosseau-Laborde, P., Marquette, C., Ilié, M., & Hofman, P. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101651 · Cited by 14
Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
Chen, H., Hu, S., Patterson, A. V., Smaill, J. B., Ding, K., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00875 · Cited by 14
Loeffler, E., Ancel, J., Dalstein, V., Deslée, G., Polette, M., & Nawrocki‐Raby, B. (2023) · Life · doi:10.3390/life14010064 · Cited by 15
Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma.
Bhardwaj, B., Revannasiddaiah, S., Bhardwaj, H., Balusu, S., & Shwaiki, A. (2016) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.10.35 · Cited by 14
Privitera, G., Luca, T., Musso, N., Vancheri, C., Crimi, N., Barresi, V., Condorelli, D. F., & Castorina, S. (2015) · Clinical and Experimental Medicine · doi:10.1007/s10238-015-0343-8 · Cited by 14
Shim, H. S., Chung, J.-H., Kim, L., Chang, S. H., Kim, W. S., Lee, G. K., Jung, S., & Jang, S. J. (2013) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2013.47.2.100 · Cited by 14
Ren, Y., Cao, L., You, M., Ji, J., Gong, Y. M., Ren, H., Xu, F., Guo, H., Hu, J., & Li, Z. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116774 · Cited by 14
The Minority Report: Targeting the Rare Oncogenes in NSCLC
McCoach, C. E., & Doebele, R. C. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0310-8 · Cited by 15
Ko, Y. S., Kim, N. Y., & Pyo, J. (2017) · The International Journal of Biological Markers · doi:10.5301/ijbm.5000271 · Cited by 14
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 15
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Reinhorn, D. J., Moskovitz, M. T., Tap, W. D., & Li, B. T. (2025) · Cancer · doi:10.1002/cncr.35780 · Cited by 14
Next generation sequencing in lung cancer: An initial experience from India
Gupta, P., Saha, K., Vinarkar, S., Banerjee, S., Choudhury, S. S., Parihar, M., Midha, D., Mukherjee, G., Lingegowda, D., Chatterjee, S., et al. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100562 · Cited by 13
Yang, G., Xu, H., Hu, J., Liu, R., Hu, P., Yang, Y., Li, W., Hao, X., Zhang, S., Xu, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806737 · Cited by 13
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)
Gaye, É., Penel, N., & Lebellec, L. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000873 · Cited by 14
Han, Y., Xiong, Y., Lu, T., Chen, R., Liu, Y., Tang, H. J., Geng, R., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121708 · Cited by 13
New Targets in Non-Small Cell Lung Cancer
Gadgeel, S. M. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0326-4 · Cited by 13
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Ganti, A. K., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Dib, E. G., Duvivier, H. L., Ahn, E. R., Behl, D., Borghaei, H., Balmanoukian, A. S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00041 · Cited by 13
Zhang, P., Nie, X., Wang, B., & Li, L. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12889 · Cited by 13
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13
Construction and Deciphering of Human Phosphorylation-Mediated Signaling Transduction Networks
Zhang, M., Li, H., He, Y., Sun, H., Li, X., Wang, L., Sun, B., Ma, L., Zhang, G., Li, J., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00249 · Cited by 13
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Zhao, J., Zhou, Z., Saw, P. E., & Song, E. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.12.008 · Cited by 16
Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.01.007 · Cited by 14
Tu, H., Yin, K., Zhao, X., Ke, E., Wu, S.-P., Li, Y.-S., Zheng, M.-M., Liu, S. M., Xu, C., Sun, Y., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13439 · Cited by 13
García, R., Torres, D., & Vázquez, C. (2024) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/d8injqfgck · Cited by 12
Wu, Y., Ni, J., Chang, X., Zhang, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13480 · Cited by 12
Amisha, F., Malik, P., Saluja, P., Gautam, N., Patel, T. H., Roy, A. M., Singh, S. R. K., & Malapati, S. J. (2023) · Onco · doi:10.3390/onco3020008 · Cited by 13
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.62 · Cited by 12
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
Ni, J., & Zhang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312820 · Cited by 12
Le, X., Robichaux, J. P., Nilsson, M. B., Vijayan, R. S. K., Ravichandran, A., Wu, J., Elamin, Y. Y., Hong, L., Pei, J., He, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61817-8 · Cited by 12
Revannasiddaiah, S., Thakur, P., Bhardwaj, B., Susheela, S. P., & Madabhavi, I. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.05.19 · Cited by 11
The expression of HER2/neu in patients with lung cancer and its associated factors
Lashkarizadeh, M., Lashkarizadeh, M., Nikian, M., & Parizi, M. K. (2023) · The Clinical Respiratory Journal · doi:10.1111/crj.13572 · Cited by 12
Takase, Y., Usui, K., Shimizu, K., Kimura, Y., Ichihara, T., Takahiro, O., Atsumi, J., Enokida, Y., Nakazawa, S., Obayashi, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171225 · Cited by 11
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
Zhang, X., Lv, J., Wu, Y., Qin, N., Ma, L., Li, X., Nong, J., Zhang, H., Zhang, Q., Yang, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01162 · Cited by 12
Yang, L., Li, Y., Du, Y. E., Guo, Y., Guo, Z., Liu, B., Liu, J., Liu, Y., Niu, H., Sun, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02302 · Cited by 10
Sompallae, R. R., Dundar, B., Guseva, N. V., Bossler, A., & Ma, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1163485 · Cited by 10
Karsaneh, O. A. A., Anber, A. A., Alqudah, M. A., Al-Mustafa, S., AlMa’aitah, H., & Sughayer, M. A. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01364-2 · Cited by 10
Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation
Wang, J., Wen, Y., Ding, G., Ding, P., Zhang, L., Liu, J., Zhang, T., & Yang, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449611 · Cited by 10
Genome editing: An essential technology for cancer treatment
Tufail, M. (2022) · Medicine in Omics · doi:10.1016/j.meomic.2022.100015 · Cited by 10
Waliany, S., Wakelee, H. A., Ramchandran, K. J., Das, M. S., Huang, J. Q., Myall, N. J., Li, C., Pagtama, J. Y., Tisch, A. H., & Neal, J. W. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.05.015 · Cited by 9
Metadata
- Authors
- Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Authors' Affiliations: 1Department of Pathology, and 2Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
- National Institutes of Health (US)
- Corresponding author
- Arcila, Maria E.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-09-15
- Volume
- 18
- Issue
- 18
- Pages
- 4910-4918
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3865806
- OpenAlex
- W2107562400
- Cited by
- 505
- References
- 48
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 36 · 2023: 40 · 2022: 39 · 2021: 52 · 2020: 42 · 2019: 30 · 2018: 42 · 2017: 30 · 2016: 23 · 2015: 43 · 2014: 37 · 2013: 31 · 2012: 4
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- HER2 mutation, lung adenocarcinoma, tyrosine kinase mutations, exon 20 insertion, never smokers, HER2 amplification, EGFR, KRAS, ALK rearrangement, molecular subtyping, clinicopathological features, molecular heterogeneity
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Prevalence, Survival Analysis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Protein Interaction Domains and Motifs, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
